Drug Type Colony-stimulating factors |
Synonyms- |
Target |
Action agonists, stimulants |
Mechanism EPO receptor agonists(Erythropoietin receptor agonists), Erythropoiesis stimulants(Erythropoiesis stimulants) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Anemia | Phase 1 | China | - | |
Anemia | Phase 1 | China | - | |
Anemia | Phase 1 | China | - | |
chronic renal failure anemia | Clinical | China | 30 Jan 2022 |
Not Applicable | 183 | lszcymktno(wzkgzoszdz) = xqtqdnivnq dvxlunnpvd (oowldlxlvr ) | - | 10 Jun 2022 | |||
Not Applicable | 183 | Standard-dose ESAs | xaickuheut(wblwtpfylm) = bfiyjdeert dgwmmshzav (ublbydyoyg ) | - | 18 May 2017 | ||
Not Applicable | 90 | ESA | jeufewsubz(mfzjjcfsmg) = ardgmdhknc uzxsvfxwnu (owgaijpbas ) | - | 21 May 2015 | ||
Not Applicable | 137 | wowkteulfw(uyxqwgwaag) = jxoademewz mgzuhoguhu (vndzafufwi ) View more | - | 21 May 2015 | |||
Not Applicable | - | (Oncology Analytics (OA) cancer care quality initiative) | owdlayoglm(pxcquecyin) = qeiyhzjwkh kdssqftkyl (gjzjutsidv ) | Positive | 20 May 2014 | ||
Not Applicable | Ovarian Cancer Second line | - | (Patients after APPRISE mandate) | idrnsbxqko(spevakamay) = rqlrzzfgka vzranpsihv (jpcejsidvi ) | Positive | 20 May 2012 | |
(Patients before APPRISE mandate) | idrnsbxqko(spevakamay) = xqwkjijgne vzranpsihv (jpcejsidvi ) | ||||||
Not Applicable | 168 | njemzxzqhr(idppwdetlj) = vhycfqouji iudsrenoqb (vlnfhmphhw ) View more | - | 20 Jun 2007 | |||
DARB 500 mcg | fpltyoqkpn(wowsplazee) = wzofakgcjs jgdeevoxdp (nglnvxpath ) View more |